Occlutech announces completion of financing by 15 million euros.
Jena, Germany, August 24, 2011- / PRNewswire / – Occlutech, a leading European company in the development of implant doctors for the treatment of structural heart disease as the permeable oral foramen, intraauricular communication and the left atrial orejuela, announced today the closure for the contribution of an investment of 15 million euros to the company. The investment was led by Interlink Investments Ltd., based in Hong Kong, and the they signed investors and partners distributors Occlutech of Japan, Switzerland, Ireland, Austria and Turkey.
Tor Peters, CEO of the company, said in a statement: “this investment allows us accelerate our I & D and present innovative and relevant products on the market in the near future.” Moreover, we hope to receive substantial payments from AGA-St.Jude as a result of a dispute began AGA in 2006 and culminated with a victory for Occlutech in the Supreme Court of Germany of 2011. “Additional funds allow us to respond aggressively to any other similar proceedings have started in an attempt to distract our attention and our appeal for the creation of relevant products that support our clients in their quest to improve and save the lives of patients”.
